Bringing personalized

medicine to

women's health

Learn about our vision

Celmatix uses big-data analytics and genomics to optimize the treatment of infertility and pave the way for proactive fertility management.

Our vision

Celmatix is committed to empowering women with genomic insights about their fertility and reproductive health.


Our products

Polaris is a powerful data analytics platform that helps fertility clinics optimize patient outcomes and improve the patient experience.


A cloud-based, HIPAA-compliant digital platform that streamlines patient intake and optimizes treatment counseling.

Polaris treatment navigator

A real-time predictive analytics engine, powered by over 500,000 treatment cycles of data, that helps physicians create personalized treatment plans and counsel their patients through important treatment milestones.

Polaris clinic manager

A digital dashboard that helps clinics optimize patient flow by allowing physicians to review patient data before the first appointment, make modifications in real time, and automatically generate progress note summaries.

Polaris patient portal

A secure, user-friendly system that improves the new patient experience by eliminating paper-based intake and consenting.

Polaris at a glance

Polaris treatment navigator

Use predictive analytics to drive better treatment outcomes

Polaris clinic manager

Streamline the new patient experience

Polaris patient portal

Simplify patient intake and consenting

Find a clinic

Top fertility clinics in the US are powered by Celmatix.

Search here to find clinic near you.

Data-driven discovery

By applying big data methods to proprietary clinical and genetic datasets, Celmatix has developed an unprecedented understanding of human reproductive function. These discoveries are driving a revolution in proactive fertility management.

We have built the world’s largest clinical dataset on fertility treatment outcomes.

We have identified over 5,200 unique regions of the human genome that impact a person’s fertility potential.

We founded the Personalized Reproductive Medicine (PReM) Initiative, a groundbreaking research alliance of leading academic institutions and fertility treatment centers across the United States, to investigate what an individual’s genetics and other metrics say about his or her overall fertility. The PReM Initiative's goal is to revolutionize how infertility is diagnosed, treated, and eventually, prevented.


23andMe and Celmatix have embarked on an ambitious research collaboration to improve infertility outcomes.